Henry and thread,
Monday March 1, i emailed investor relations with four questions. Within minutes,
Pam Wallace answered two of my questions and said she was referring the other two to Dr. Steven Reich, Senior Vice President, Clinical Research.
This morning, I'm please to say that Pam sent me another email with more
information. So it looks like Ligand investor relations is back on track, though I too miss Susan Atkins.
-------------------------------------------------------------------
>> LGND just has too many drugs approved and almost approved to keep straight :-)
Henry, I'm trying to keep all those drugs and trials straight, and have two questions for you (questions I forgot to ask IR).
I know that Panretin and LGD1550 (a RAR) have been in trials for solid tumors.
There was a report on LGD1550 at ASCO last year.
prnewswire.com
This 5/18/98 PR says "The Company plans to begin Phase II studies with LGD1550 in patients with cervical and head and neck cancers after determining the recommended dosage levels, which will be based on review of Phase I data."
1) Have you heard anything more about LGD1550 ?
----------------------
I know that Targretin was in a European Phase II for diabetes, and is in Phase III for CTCL.
Your 9/12/96 thread header says
"One of LGND's retinoids, Targretin, is in advanced clinical trials for a wide range of cancers."
I've been looking through old press releases (dating back to August 1996), and i can't find much.
A December 9, 1996 press release, related to a Targretin CTCL presentation at an American Society of Hematology Conference says
"Oral Targretin (LGD1069) is in Phase II/III trials in patients with advanced lung cancer, and in Phase IIb trials in patients with head and neck cancer, Kaposi's sarcoma (KS), and kidney cancer. Earlier this year investigators at Memorial Sloan-Kettering Cancer Center and Georgetown University Medical Center reported stabilization of disease in some lung cancer patients treated with Targretin Oral capsules."
2) Have you seen any updates or status reports since the above PR?
Thanks in advance,
Cheryl |
